
Francesco Ernesto Pontieri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6555783/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Validation of the Canadian Occupational Performance Measure in Italian Parkinson's Disease Clients. Physical and Occupational Therapy in Geriatrics, 2022, 40, 26-37.	0.4	2
2	Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. Journal of Parkinson's Disease, 2022, 12, 917-926.	2.8	9
3	Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease. Neurological Sciences, 2022, , 1.	1.9	1
4	The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study. Aging Clinical and Experimental Research, 2021, 33, 1689-1692.	2.9	7
5	Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. Journal of Neural Transmission, 2021, 128, 273-277.	2.8	19
6	Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. Journal of Personalized Medicine, 2021, 11, 51.	2.5	9
7	Immune System and Neuroinflammation in Idiopathic Parkinson's Disease: Association Analysis of Genetic Variants and miRNAs Interactions. Frontiers in Genetics, 2021, 12, 651971.	2.3	8
8	Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study. Neurological Research, 2021, 43, 950-954.	1.3	9
9	Percutaneous endoscopic gastrojejunostomy in pediatric intestinal pseudo-obstruction. Nutrition, 2021, 86, 111174.	2.4	4
10	<scp>DUOGLOBE</scp> : One‥ear Outcomes in a <scp>Realâ€World</scp> Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 1061-1074.	1.5	22
11	Cerebellar GABA Levels and Cognitive Interference in Parkinson's disease and Healthy Comparators. Journal of Personalized Medicine, 2021, 11, 16.	2.5	6
12	Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease. Sensors, 2021, 21, 128.	3.8	38
13	Application of the â€~5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. Neurodegenerative Disease Management, 2020, 10, 309-323.	2.2	33
14	<p>Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2899-2912.	2.2	9
15	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. Journal of Neural Transmission, 2020, 127, 881-891.	2.8	8
16	Drug Choices and Advancements for Managing Depression in Parkinson's Disease. Current Neuropharmacology, 2020, 18, 277-287.	2.9	31
17	Urinary retention discriminates multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 1926-1928.	3.9	19
18	Action Observation With Dual Task for Improving Cognitive Abilities in Parkinson's Disease: A Pilot Study. Frontiers in Systems Neuroscience, 2019, 13, 7.	2.5	11

#	Article	IF	CITATIONS
19	Gender specific decrease of a set of circulating N-acylphosphatidyl ethanolamines (NAPEs) in the plasma of Parkinson's disease patients. Metabolomics, 2019, 15, 74.	3.0	9
20	Early distinction of Parkinsonâ€variant multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 440-441.	3.9	21
21	Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. Brain and Behavior, 2019, 9, e01448.	2.2	9
22	Alpha-synuclein in salivary gland as biomarker for Parkinson's disease. Reviews in the Neurosciences, 2019, 30, 455-462.	2.9	19
23	Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. Journal of Neurology, 2018, 265, 1124-1137.	3.6	52
24	Orthostatic hypotension acutely impairs executive functions in Parkinson's disease. Neurological Sciences, 2018, 39, 1459-1462.	1.9	10
25	Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological/neuropsychiatric correlates. Parkinsonism and Related Disorders, 2018, 54, 62-67.	2.2	32
26	Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study. Neurological Sciences, 2018, 39, 141-143.	1.9	10
27	Psychiatric profile of motor subtypes of de novo drugâ€naÃ⁻ve Parkinson's disease patients. Brain and Behavior, 2018, 8, e01094.	2.2	4
28	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
29	Phosphorylated α-synuclein immunoreactivity in nerve fibers from minor salivary glands in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 38, 99-101.	2.2	11
30	Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease. Parkinsonism and Related Disorders, 2017, 45, 50-56.	2.2	31
31	Plasma Exchangeâ€responsive Tardive Delayed Pseudochoreoathetosis in a Patient with Antiâ€Hu Neuronopathy. Movement Disorders Clinical Practice, 2017, 4, 887-888.	1.5	0
32	Supine hypertension in Parkinson's disease and multiple system atrophy. Clinical Autonomic Research, 2016, 26, 97-105.	2.5	87
33	Unraveling predictors affecting compliance to MRI inÂParkinson'sÂdisease. Parkinsonism and Related Disorders, 2015, 21, 964-967.	2.2	2
34	Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson׳s disease. European Neuropsychopharmacology, 2015, 25, 69-76.	0.7	35
35	Treatment with botulinum toxin for anti-MAG neuropathy-related arm tremor. Neurological Sciences, 2015, 36, 333-334.	1.9	8
36	Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson's disease patients. Parkinsonism and Related Disorders, 2015, 21, 1096-1100.	2.2	36

#	Article	IF	CITATIONS
37	Botulinum toxin type A for Holmes tremor secondary to thalamic hemorrhage. Neurological Sciences, 2015, 36, 1935-1936.	1.9	10
38	On the relationship between side of onset and cognition in Parkinson disease: Response from the authors. Parkinsonism and Related Disorders, 2015, 21, 1481-1482.	2.2	1
39	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. Parkinsonism and Related Disorders, 2015, 21, 1393-1397.	2.2	33
40	The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease. Journal of Neurology, 2014, 261, 1126-1132.	3.6	14
41	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. Journal of Neurology, 2014, 261, 1291-1299.	3.6	47
42	The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study. European Journal of Medical Research, 2013, 18, 60.	2.2	12
43	The potential prognostic role of cardiovascular autonomic failure in αâ€synucleinopathies. European Journal of Neurology, 2013, 20, 231-235.	3.3	61
44	HEDONIC TONE AND ITS MOOD AND COGNITIVE CORRELATES IN PARKINSON'S DISEASE. Depression and Anxiety, 2013, 30, 85-91.	4.1	11
45	Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia. Aging Clinical and Experimental Research, 2013, 25, 601-603.	2.9	9
46	Depressive symptoms in Parkinson's disease and in non-neurological medical illnesses. Neuropsychiatric Disease and Treatment, 2013, 9, 389.	2.2	8
47	Blood Dendritic Cell Frequency Declines in Idiopathic Parkinson's Disease and Is Associated with Motor Symptom Severity. PLoS ONE, 2013, 8, e65352.	2.5	38
48	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 76-82.	1.9	82
49	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. Journal of Neurology, 2012, 259, 2621-2631.	3.6	188
50	Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 871-875.	2.2	23
51	Alexithymia Is a Non-Motor Symptom of Parkinson Disease. American Journal of Geriatric Psychiatry, 2012, 20, 133-141.	1.2	38
52	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Neurological Sciences, 2012, 33, 585-593.	1.9	18
53	Regional cortical thickness and cognitive functions in nonâ€demented Parkinson's disease patients: a pilot study. European Journal of Neurology, 2012, 19, 172-175.	3.3	26
54	Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease. Pharmacological Reports, 2011, 63, 1056-1060.	3.3	4

#	Article	IF	CITATIONS
55	Choline acetyltransferase of the common type immunoreactivity in the rat brain following different heroin treatments: A pilot study. Journal of Chemical Neuroanatomy, 2011, 41, 111-121.	2.1	3
56	The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders. Current Neuropharmacology, 2011, 9, 278-288.	2.9	76
57	Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease. Movement Disorders, 2011, 26, 355-357.	3.9	10
58	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. Journal of Neurology, 2010, 257, 5-14.	3.6	140
59	Dopaminergic system in peripheral blood mononuclear cells in Parkinson's disease. Movement Disorders, 2010, 25, 125-126.	3.9	6
60	Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease. Journal of the International Neuropsychological Society, 2010, 16, 867-876.	1.8	49
61	Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain, 2010, 133, 3423-3433.	7.6	374
62	Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study. Neurological Research, 2009, 31, 74-76.	1.3	6
63	Central and peripheral dopamine transporter reduction in Parkinson's disease. Neurological Research, 2009, 31, 687-691.	1.3	19
64	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Movement Disorders, 2009, 24, 1641-1649.	3.9	1,171
65	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy. Journal of Neural Transmission, 2009, 116, 161-165.	2.8	13
66	An exploratory case-control study on spinal and bulbar forms of amyotrophic lateral sclerosis in the province of Rome. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 361-369.	2.1	39
67	Neuropharmacology and behavior in planarians: Translations to mammals. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2008, 147, 399-408.	2.6	84
68	The recognition of facial emotion expressions in Parkinson's disease. European Neuropsychopharmacology, 2008, 18, 835-848.	0.7	97
69	Hemiparkinsonism due to frontal meningioma. Acta Neurologica Belgica, 2008, 108, 29-32.	1.1	13
70	Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. Journal of Neural Transmission, 2007, 114, 935-938.	2.8	34
71	Prodromal non-motor symptoms of Parkinson's disease. Neuropsychiatric Disease and Treatment, 2007, 3, 145-151.	2.2	83
72	Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis. European Journal of Neurology, 2006, 13, 416-418.	3.3	25

#	Article	IF	CITATIONS
73	Effects of the intravenous administration of [Lys7]dermorphin on local cerebral glucose utilization in the rat. European Journal of Pharmacology, 2006, 544, 17-20.	3.5	1
74	Changes in neuropeptide FF and NPY immunohistochemical patterns in rat brain under heroin treatment. Brain Research, 2006, 1083, 151-158.	2.2	17
75	Amyotrophic lateral sclerosis and sports: a case–control study. European Journal of Neurology, 2005, 12, 223-225.	3.3	47
76	Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurological Sciences, 2005, 26, 285-287.	1.9	39
77	Increased Lymphocyte Dopamine β-Hydroxylase Immunoreactivity in Alzheimer's Disease: Compensatory Response to Cholinergic Deficit?. Dementia and Geriatric Cognitive Disorders, 2004, 18, 338-341.	1.5	15
78	Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications. Current Neuropharmacology, 2004, 2, 1-7.	2.9	6
79	Adrenal dysregulation in amyotrophic lateral sclerosis. Journal of Endocrinological Investigation, 2003, 26, RC23-RC25.	3.3	34
80	Cannabinoid-induced stimulation of motor activity in planaria through an opioid receptor-mediated mechanism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 65-68.	4.8	23
81	Heroin sensitization as mapped by c-Fos immunoreactivity in the rat striatum. Brain Research, 2002, 933, 144-149.	2.2	26
82	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. Journal of Neural Transmission, 2001, 108, 803-807.	2.8	65
83	Behavioral sensitization to WIN55212.2 in rats pretreated with heroin. Brain Research, 2001, 898, 178-180.	2.2	32
84	Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. European Journal of Pharmacology, 2001, 421, R1-R3.	3.5	80
85	Effects of intra-VTA injection of neurotensin on local cerebral glucose utilization in freely moving ratsâ~†,â~†â~†. Peptides, 2000, 21, 1751-1753.	2.4	5
86	Acetylcholine/dopamine interaction in planaria. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 2000, 125, 225-231.	0.5	40
87	Drug Addiction as a Disorder of Associative Learning: Role of Nucleus Accumbens Shell/Extended Amygdala Dopamine. Annals of the New York Academy of Sciences, 1999, 877, 461-485.	3.8	204
88	Metabolic Mapping of the Effects of Win 55212–2 Intravenous Administration in the Rat. Neuropsychopharmacology, 1999, 21, 773-776.	5.4	29
89	Treatment with 6-hydroxydopamine in planaria (Dugesia gonocephala s.l.): morphological and behavioral study. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1999, 123, 201-207.	0.5	9
90	Opioid–dopamine interaction in planaria: a behavioral study. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1999, 124, 51-55.	0.5	34

#	Article	IF	CITATIONS
91	Effects of haloperidol on the expression of lymphocyte dopamine receptor mRNAS in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1999, 23, 851-859.	4.8	3
92	Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. NeuroReport, 1999, 10, 2907-2910.	1.2	58
93	Functional correlates of nicotine administration: similarity with drugs of abuse. Journal of Molecular Medicine, 1998, 76, 193-201.	3.9	25
94	Dopamine receptor mRNAs in the rat lymphocytes. Life Sciences, 1998, 62, 1919-1925.	4.3	33
95	Increased motor response to cocaine administration following recovery from chronic corticosterone treatment in the rat. European Neuropsychopharmacology, 1998, 8, 43-46.	0.7	5
96	Functional correlates of heroin sensitization in the rat brain. European Journal of Pharmacology, 1997, 335, 133-137.	3.5	19
97	Increased functional response to cocaine challenge following recovery from chronic corticosterone in the rat. European Journal of Pharmacology, 1997, 336, 159-162.	3.5	1
98	Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common µ ₁ Opioid Receptor Mechanism. Science, 1997, 276, 2048-2050.	12.6	1,059
99	Contribution of Blockade of the Noradrenaline Carrier to the Increase of Extracellular Dopamine in the Rat Prefrontal Cortex by Amphetamine and Cocaine. European Journal of Neuroscience, 1997, 9, 2077-2085.	2.6	153
100	Differential effects of acute administration of clozapine or haloperidol on local cerebral glucose utilization in the rat1This study was partially supported by the Italian Health Department.1. Brain Research, 1997, 768, 273-278.	2.2	18
101	Dopamine release in striatal slices of rats previously submitted to electroconvulsive shock. Brain Research, 1997, 774, 239-241.	2.2	2
102	Electroconvulsive shock blocks the opioid-mediated inhibition of dopamine release in rat striatal slices. Journal of Neural Transmission, 1997, 104, 805-810.	2.8	2
103	Intravenous morphine increases glucose utilization in the shell of the rat nucleus accumbens. European Journal of Pharmacology, 1996, 302, 49-51.	3.5	26
104	Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. Journal of Neurology, 1996, 243, 422-425.	3.6	44
105	Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 1996, 382, 255-257.	27.8	1,015
106	Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 12304-12308.	7.1	783
107	Selective metabolic activation by apomorphine in striosomes of denervated striatum in MPTP-induced hemiparkinsonian monkeys. NeuroReport, 1995, 6, 1330-1332.	1.2	3
108	Functional correlates of repeated administration of cocaine and apomorphine in the rat. European Journal of Pharmacology, 1995, 284, 205-209.	3.5	18

#	Article	IF	CITATIONS
109	Psychostimulant drugs increase glucose utilization in the shell of the rat nucleus accumbens. NeuroReport, 1994, 5, 2561-2564.	1.2	46
110	Local cerebral glucose utilization after D1 receptor stimulation in 6-OHDA lesioned rats: Effect of sensitization (priming) with a dopaminergic agonist. Synapse, 1993, 13, 264-269.	1.2	30
111	Metabolic mapping of the synergism between MK-801 and SKF 38393 in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. Synapse, 1992, 12, 255-260.	1.2	10
112	Alterations in opiate receptor binding in MPTP-induced hemiparkinsonian monkeys. Neuroscience Letters, 1991, 127, 155-159.	2.1	8
113	Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats. Psychopharmacology, 1990, 102, 175-182.	3.1	47